ABIO - ARCAバイオファ―マ (ARCA biopharma Inc.)

ABIOのニュース

   ARCA biopharma''s Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study  2022/04/01 11:09:26 Benzinga
ARCA biopharma Inc (NASDAQ: ABIO ) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19. In the 160-patient trial, both doses of rNAPc2 demonstrated a treatment benefit; however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D-dimer level from Baseline to Day 8 … Full story available on Benzinga.com
   ABIO stock falls as COVID-19 trial fails to meet key goal (NASDAQ:ABIO)  2022/03/31 20:42:14 Seeking Alpha
Arca Biopharma (ABIO) is trading ~28% lower in the post-market Thursday after the clinical-stage biotech announced that its experimental COVID-19 therapy rNAPc2 failed to meet the…
   ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial  2022/03/31 20:15:00 GlobeNewswire
WESTMINSTER, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced results for ASPEN-COVID-19 , a 160 patient Phase 2b clinical trial evaluating rNAPc2, a highly potent and specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D-dimer level from Baseline to Day 8 compared to standard of care heparin.
   ARCA biopharma GAAP EPS of -$1.39 (NASDAQ:ABIO)  2022/03/14 21:40:36 Seeking Alpha
ARCA biopharma press release (ABIO): FY GAAP EPS of -$1.39.FY Cash and cash equivalents of $53.4M
   ARCA biopharma Inc Shares Approach 52-Week Low - Market Mover  2022/01/09 19:19:27 Kwhen Finance
ARCA biopharma Inc (ABIO) shares closed today at 1.5% above its 52 week low of $2.01, giving the company a market cap of $29M. The stock is currently down 5.1% year-to-date, down 51.7% over the past 12 months, and down 96.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 1.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -45.1% The company's stock price performance over the past 12 months lags the peer average by -1436.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   ARCA biopharma Inc Shares Close in on 52-Week Low - Market Mover  2021/12/30 07:02:38 Kwhen Finance
ARCA biopharma Inc (ABIO) shares closed today at 1.4% above its 52 week low of $2.17, giving the company a market cap of $32M. The stock is currently down 44.4% year-to-date, down 46.4% over the past 12 months, and down 95.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 17.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -268.9% The company's stock price performance over the past 12 months lags the peer average by -299.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Financial Survey: ARCA biopharma (ABIO) & Its Peers  2021/12/13 11:20:42 Transcript Daily
ARCA biopharma (NASDAQ: ABIO) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its rivals? We will compare ARCA biopharma to related businesses based on the strength of its earnings, institutional ownership, dividends, profitability, risk, valuation and analyst recommendations. Risk & Volatility ARCA biopharma has []
   Head-To-Head Contrast: ARCA biopharma (ABIO) and Its Peers  2021/12/11 09:12:42 Dakota Financial News
ARCA biopharma (NASDAQ: ABIO) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its rivals? We will compare ARCA biopharma to related companies based on the strength of its earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Risk and Volatility ARCA biopharma has []
   Contrasting ARCA biopharma (ABIO) & Its Peers  2021/12/10 10:58:42 Dakota Financial News
ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it compare to its peers? We will compare ARCA biopharma to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, profitability, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of current []
   ARCA biopharma (ABIO) vs. Its Peers Critical Analysis  2021/12/09 11:36:46 Transcript Daily
ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it weigh in compared to its peers? We will compare ARCA biopharma to related companies based on the strength of its institutional ownership, dividends, profitability, valuation, analyst recommendations, earnings and risk. Valuation & Earnings This table compares []
   Head-To-Head Comparison: ARCA biopharma (ABIO) versus The Competition  2021/12/03 04:10:42 Dakota Financial News
ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it weigh in compared to its peers? We will compare ARCA biopharma to related businesses based on the strength of its valuation, risk, analyst recommendations, dividends, institutional ownership, profitability and earnings. Volatility and Risk ARCA biopharma has []
   ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19  2021/12/02 13:30:00 Intrado Digital Media
WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in ASPEN - COVID - 19 , the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19. 160 patients were enrolled at clinical investigative sites in the United States, Argentina and Brazil. The Company anticipates reporting topline data from the clinical trial in the first quarter of 2022.
   Head to Head Survey: ARCA biopharma (ABIO) vs. Its Rivals  2021/11/27 07:48:41 Transcript Daily
ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it contrast to its peers? We will compare ARCA biopharma to related companies based on the strength of its valuation, profitability, earnings, institutional ownership, risk, analyst recommendations and dividends. Profitability This table compares ARCA biopharma and its []
   Reviewing ARCA biopharma (ABIO) & Its Rivals  2021/11/26 04:17:01 Dakota Financial News
ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it weigh in compared to its peers? We will compare ARCA biopharma to related companies based on the strength of its risk, profitability, earnings, institutional ownership, dividends, analyst recommendations and valuation. Analyst Recommendations This is a breakdown []
   Minerva Advisors LLC Buys FreightCar America Inc, Nicolet Bankshares Inc, Lumos Pharma Inc, ...  2021/11/12 21:38:25 GuruFocus
Related Stocks: RAIL , DGICA , NCBS , LUMO , NECB , ABIO , MFNC ,

calendar